Levi & Korsinsky, LLP announces that a KPTI class action lawsuit has been commenced on behalf of investors who purchased Karyopharm Therapeutics, Inc. (KPTI) securities between March 2, 2017 and February 22, 2019. For more on the Karyopharm Therapeutics Class Action please contact us today.

According to the Karyopharm Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. (2) Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. (3) As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

TO LEARN MORE ABOUT THE KPTI CLASS ACTION, VISIT: https://www.zlk.com/pslra-1/karyopharm-therapeutics-inc-loss-form?wire=3

If you suffered a loss in Karyopharm Therapeutics you have until September 23, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com